3,648 reports of this reaction
1.5% of all CARVEDILOL reports
#20 most reported adverse reaction
MYOCARDIAL INFARCTION is the #20 most commonly reported adverse reaction for CARVEDILOL, manufactured by Waylis Therapeutics LLC. There are 3,648 FDA adverse event reports linking CARVEDILOL to MYOCARDIAL INFARCTION. This represents approximately 1.5% of all 250,588 adverse event reports for this drug.
Patients taking CARVEDILOL who experience myocardial infarction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYOCARDIAL INFARCTION is a less commonly reported adverse event for CARVEDILOL, but still significant enough to appear in the safety profile.
In addition to myocardial infarction, the following adverse reactions have been reported for CARVEDILOL:
The following drugs have also been linked to myocardial infarction in FDA adverse event reports:
MYOCARDIAL INFARCTION has been reported as an adverse event in 3,648 FDA reports for CARVEDILOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYOCARDIAL INFARCTION accounts for approximately 1.5% of all adverse event reports for CARVEDILOL, making it a notable side effect.
If you experience myocardial infarction while taking CARVEDILOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.